We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Docetaxel Plus Neoadjuvant AC Increases Pathologic Complete Responses in Breast Cancer

Feb 1, 2002
Volume: 
11
Issue: 
2
  • Breast Cancer

SAN ANTONIO—The sequential use of docetaxel (Taxotere) after Adriamycin (doxorubicin)/cyclophosphamide (AC) as a neoadjuvant regimen in
primary operable breast cancer essentially doubles the rate of pathologic
complete responses (CRs), according to final response data from the National
Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-27.

NSABP B-27, reported at the 24th Annual San Antonio Breast Cancer Symposium
(abstract 5), evaluated neoadjuvant AC (60/600 mg/m² every 3 weeks) and
docetaxel (100 mg/m² every 3 weeks) in 2,411 patients with large operable
breast tumors.

Patients were randomized to four cycles of AC followed by surgery (group 1);
four cycles of AC followed by four cycles of docetaxel and then surgery (group
2); or four cycles of AC, then surgery, followed by four cycles of docetaxel
(group 3). For purposes of the response rate analyses, groups 1 and 3 were
combined into the AC group and compared with group 2, the AC/T group.

The sequential use of docetaxel after preoperative AC increased the breast
tumor pathologic complete response rate by 87%, clinical complete response rate
by 60%, and lymph-node-negative status by 15%, reported Harry D. Bear, MD, PhD,
professor of surgery, Virginia Commonwealth University, Richmond.

The prior NSABP B-18 trial showed improved survival in patients who achieved
a pathologic complete response; however, in that trial, neoadjuvant AC produced
only a 13% pathologic complete response rate. The aim of B-27 was to determine
whether the addition of a taxane to AC neoadjuvant therapy would improve
pathologic complete response rates and multiple outcomes.

Survival analyses will be conducted later, but Dr. Bear commented on the
potential effect. "We know that pathologic response to a given regimen
predicts overall outcome in terms of survival. But we don’t know whether that
is because of the treatment or the biology of the tumor. This trial will be one
of the first to answer the question, ‘If you change the treatment to increase
the response rate, will you also get an improved survival?’

If the docetaxel group has a better survival, he said, "this will tell
us that local response is truly a surrogate for outcome in terms of survival.
We can then use this in subsequent trials as an endpoint. I am very optimistic,
but we don’t yet have the data on long-term follow-up."

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.